Genetic association between PER3 genetic polymorphisms and cancer susceptibility

Medicine (United States)

Volumn 94, Issue 13, 2015, Pages

  Geng, Peiliang ^a   Ou, Juanjuan ^a   Li, Jianjun ^a   Wang, Ning ^a   Xie, Ganfeng ^a   Sa, Rina ^a   Liu, Chen ^a   Xiang, Lisha ^a   Liang, Houjie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCADIAN RHYTHM SIGNALING PROTEIN; PERIOD 3 PROTEIN; UNCLASSIFIED DRUG; PER3 PROTEIN, HUMAN;

ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; META ANALYSIS; NEOPLASM; PRIORITY JOURNAL; SYSTEMATIC REVIEW; CIRCADIAN RHYTHM; GENETIC PREDISPOSITION; GENETICS; RISK ASSESSMENT;

CIRCADIAN CLOCKS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NEOPLASMS; PERIOD CIRCADIAN PROTEINS; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 84929469551     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000568     Document Type: Article

References (27)

1. Lowrey PL, Takahashi JS. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet. 2004;5:407-441.
2. Kondratov RV, Gorbacheva VY, Antoch MP. The role of mammalian circadian proteins in normal physiology and genotoxic stress responses. Curr Top Dev Biol. 2007;78:173-216.
3. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517-549.
4. Yu EA, Weaver DR. Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging (Albany NY). 2011;3:479-493.
5. Mazzoccoli G, De Cata A, Piepoli A, et al. The circadian clock and the hypoxic response pathway in kidney cancer. Tumour Biol. 2014;35:1-7.
6. Lee C, Etchegaray JP, Cagampang FR, et al. Posttranslational mechanisms regulate the mammalian circadian clock. Cell. 2001;107:855-867.
7. Stevens RG. Testing the light-at-night (LAN) theory for breast cancer causation. Chronobiol Int. 2011;28:653-656.
8. Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology. 2005;16:254-258.
9. Blask DE, et al. Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J Pineal Res. 2011;51:259-269.
10. Band PR, et al. Cohort study of Air Canada pilots: mortality, cancer incidence, and leukemia risk. Am J Epidemiol. 1996;143:137-143.
11. Irvine D, Davies DM. British Airways flightdeck mortality study, 1950-1992. Aviat Space Environ Med. 1999;70:548-555.
12. Pukkala E, et al. Cancer incidence among 10, 211 airline pilots: a Nordic study. Aviat Space Environ Med. 2003;74:699-706.
13. Straif K, et al. Carcinogenicity of shift-work, painting, and firefighting. Lancet Oncol. 2007;8:1065-1066.
14. Xia HC, et al. Deregulated expression of the Per1 and Per2 in human gliomas. Can J Neurol Sci. 2010;37:365-370.
15. Zhu Y, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res. 2009;69:9315-9322.
16. Grundy A, et al. Shift work, circadian gene variants and risk of breast cancer. Cancer Epidemiol. 2013;37:606-612.
17. Zienolddiny S, et al. Analysis of polymorphisms in the circadianrelated genes and breast cancer risk in Norwegian nurses working night shifts. Breast Cancer Res. 2013;15:R53.
18. Chu LW, et al. Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis. 2008;11:342-348.
19. Dai H, et al. The role of polymorphisms in circadian pathway genes in breast tumorigenesis. Breast Cancer Res Treat. 2011;127:531-540.
20. Karantanos T, et al. Association of the clock genes polymorphisms with colorectal cancer susceptibility. J Surg Oncol. 2013;108:563-567.
21. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
22. Madden MH, et al. Circadian pathway genes in relation to glioma risk and outcome. Cancer Causes Control. 2014;25:25-32.
23. Zhu Y, Brown HN, Zhang Y, et al. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev. 2005;14:268-270.
24. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418:935-941.
25. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003;3:350-361.
26. Oshima T, et al. Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. Oncol Rep. 2011;25:1439-1446.
27. Climent J, et al. Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol. 2010;28:3770-3778.